Bioequivalence Study of Two Formulations of Tablets Ramipril 10 mg in Healthy Volunteers Under Fasting Conditions
Status:
Recruiting
Trial end date:
2022-11-17
Target enrollment:
Participant gender:
Summary
This is an open-labeled, randomized, two period, single-center, crossover, comparative study,
where each participant will be randomly assigned to the reference (Tritace®, 10 mg tablets)
or the test (Ramipril, 10 mg tablets) formulation in each period of study (sequences
Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are
bioequivalent